Table 2.
Association of HIF-1α, c-Met, CA9 and GLUT1 IHC expression with clinicopathological characteristics in cervical cancer
| |
HIF-1α |
c-Met |
CA9 |
GLUT1 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean score (95% CI) | p value | N | Mean score (95% CI) | p value | N | Mean score (95% CI) | p value | N | Mean score (95% CI) | p value | |
|
Diagnostic category |
|
< 0.001 |
|
|
< 0.001 |
|
|
< 0.001 |
|
|
< 0.001 |
|
| Normal a |
313 |
4.4 (4.0-4.7) |
|
346 |
0.4 (0.3-0.6) |
|
314 |
0.0 (0.0-0.0) |
|
357 |
0.9 (0.7-1.1) |
|
| Low grade CIN b |
54 |
5.1 (4.3-5.9) |
|
62 |
0.6 (0.2-1.0) |
|
55 |
0.4 (0.0-0.8) |
|
40 |
1.8 (0.9-2.7) |
|
| High grade CIN b |
104 |
5.4 (4.9-6.0) |
|
115 |
0.7 (0.4-0.9) |
|
132 |
1.9 (1.3-2.5) |
|
121 |
2.2 (1.8-2.7) |
|
| CIS b |
56 |
5.7 (4.9-6.4) |
|
60 |
1.7 (1.0-2.4) |
|
69 |
1.3 (0.6-1.9) |
|
73 |
2.4 (1.7-3.6) |
|
| Cervical cancer b |
151 |
5.4 (4.9-6.0) |
|
152 |
4.7 (4.0-5.3) |
|
144 |
2.1 (1.5-2.8) |
|
162 |
4.0 (3.3-4.6) |
|
|
FIGO stage |
|
|
< 0.001 |
|
|
0.019 |
|
|
0.149 |
|
0.243 |
|
| I |
96 |
4.6 (4.0-5.2) |
|
98 |
4.2 (3.4-5.0) |
|
95 |
1.7 (0.9-2.4) |
|
114 |
4.3 (3.5-5.1) |
|
| II |
50 |
6.9 (5.9-7.9) |
|
49 |
5.2 (3.9-6.4) |
|
45 |
2.9 (1.6-4.1) |
|
43 |
3.1 (2.1-4.0) |
|
| IV |
5 |
6.0 (2.4-9.5) |
|
5 |
9.2 (3.7-14.6) |
|
4 |
4.0 (−5.0-13.0) |
|
5 |
4.0 (0.4-7.5) |
|
|
Tumor differentiation |
|
0.350 |
|
|
0.195 |
|
|
0.298 |
|
0.169 |
||
| Well+Moderate |
105 |
5.6 (4.9-6.2) |
|
107 |
4.4 (3.7-5.2) |
|
105 |
2.4 (1.6-3.1) |
|
115 |
4.1 (3.3-4.8) |
|
| Poor |
40 |
5.0 (3.9-6.1) |
|
40 |
5.4 (4.0-6.9) |
|
37 |
1.5 (0.3-2.6) |
|
41 |
3.1 (1.8-4.3) |
|
|
Cell Type |
|
|
0.010 |
|
|
0.325 |
|
|
0.040 |
|
0.001 |
|
| SCC |
119 |
5.8 (5.2-6.4) |
|
118 |
4.5 (3.7-5.2) |
|
111 |
1.6 (1.0-2.3) |
|
130 |
4.4 (3.7-5.2) |
|
| Other |
32 |
4.1 (2.8-5.4) |
|
33 |
5.3 (3.7-6.9) |
|
33 |
3.7 (1.8-5.5) |
|
31 |
1.9 (0.9-2.8) |
|
|
Tumor size |
|
|
0.210 |
|
|
0.195 |
|
|
0.851 |
|
0.947 |
|
| < 4cm |
104 |
5.2 (4.6-5.8) |
|
106 |
4.9 (4.1-5.7) |
|
100 |
2.2 (1.4-2.9) |
|
119 |
4.0 (3.2-4.8) |
|
| ≥ 4cm |
47 |
5.9 (4.9-7.0) |
|
46 |
4.1 (2.9-5.3) |
|
44 |
2.0 (0.9-3.1) |
|
43 |
3.9 (2.8-5.0) |
|
|
LVSI |
|
|
0.725 |
|
|
0.001 |
|
|
0.998 |
|
0.801 |
|
| Negative |
73 |
5.0 (4.2-5.7) |
|
74 |
3.6 (2.7-4.4) |
|
65 |
2.0 (1.0-3.0) |
|
84 |
4.0 (3.1-4.9) |
|
| Positive |
62 |
5.1 (4.3-6.0) |
|
62 |
5.9 (4.8-7.0) |
|
63 |
2.0 (1.0-3.0) |
|
63 |
4.3 (3.2-5.3) |
|
|
LN metastasis |
|
|
< 0.001 |
|
|
0.010 |
|
|
0.820 |
|
0.001 |
|
| Negative |
100 |
4.4 (3.9-5.0) |
|
102 |
4.0 (3.3-4.8) |
|
95 |
2.0 (1.2-2.8) |
|
113 |
4.5 (3.7-5.4) |
|
| Positive | 37 | 6.7 (5.5-7.9) | 36 | 6.3 (4.8-7.9) | 35 | 2.2 (0.8-3.6) | 36 | 2.6 (1.6-3.6) | ||||
Some data of tumor differentiation, LVSI and LN metastasis are not available on retrospective chart review. SCC, squamous cell carcinoma; LVSI, lymphovascular space invasion; a normal sample was constructed with nonadjacent normal epithelium from tumor in same patient, bIHC staining of each marker was evaluated with available tumor cores from 209 CIN, 74 CIS and 179 cancer cores.